Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including Population Health, Equity & Outcomes; Evidence-Based Oncology™; and The Center for Biosimilars®. She has been working on AJMC since 2014 and has been with AJMC’s parent company, MJH Life Sciences®, since 2011.
She has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.
PALOMA-2 Reinforces Efficacy of SubQ Amivantamab in EGFR-Mutated NSCLC: Sun Lim Min, MD, PhD
September 9th 2025Subcutaneous amivantamab plus chemotherapy offers an equally effective treatment for EGFR exon 20 insertion non–small cell lung cancer (NSCLC), mirroring PAPILLON results of the intravenous formulation, explained Sun Lim Min, MD, PhD.
Clinical Advances in EGFR-Mutated NSCLC: Insights From MARIPOSA and FLAURA2
September 7th 2025Treatment of EGFR-mutated non–small cell lung cancer (NSCLC) is shifting toward next-generation sequencing and combination regimens that improve survival but increase toxicity, requiring individualized care.
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
September 7th 2025Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
Medicaid Cuts Could Cause Legislators to Reevaluate Access to Care for Children: Chris Johnson, MBA
September 5th 2025Medicaid cuts could be devastating to areas where health care deserts are prevalent, especially in children, making it vital that legislators understand the potential gap in care to help close it.
Rusfertide Poised to Transform Polycythemia Vera Care: Andrew Kuykendall, MD
September 2nd 2025Rusfertide has received orphan drug, fast track, and breakthrough therapy designations from the FDA, and in this interview, Andrew Kuykendall, MD, Moffitt Cancer Center, emphasizes the critical need for therapies that offer a sense of normalcy to individuals with polycythemia vera.
Uncertainty Metrics in AI-Assisted Mammograms Screenings: Sarah Verboom, PhD Candidate
August 25th 2025Artificial intelligence (AI) can reduce radiologist workload for breast cancer screenings and mammograms, but their review of the results is still crucial, explained Sarah Verboom of Radboud University Medical Center.
Weighing Relapse Risk Against Benefit in Advanced NSCLC Immunotherapy: Jonathan Thompson, MD, MS
August 22nd 2025In advanced non–small cell lung cancer (NSCLC), discontinuing immunotherapy after 2 years can maintain durable responses while reducing financial and toxicity burdens, with decisions guided by residual disease testing and shared decision-making, explained Jonathan Thompson, MD, MS.
AI-Assisted Mammography, Practical Applications: Sarah Verboom, PhD Candidate
August 21st 2025Artificial intelligence (AI) can enhance breast cancer screenings by prioritizing cases, allowing radiologists to focus on complex diagnoses and improve detection rates, explained Sarah Verboom of Radboud University Medical Center.